Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

MRD at the end of induction and EFS in T-cell lymphoblastic lymphoma: Children’s Oncology Group trial AALL1231

Blood (2024) 143 (20): 2053–2058.

https://doi.org/10.1182/blood.2023021184

Published: 2024

Includes: Supplemental data

Journal Articles

Neonatal Hemophagocytic Lymphohistiocytosis: Scoping Review and Analysis of 205 Cases

Lincoln Kranz, Wyatt Hahn, Whitney Thompson, Roland Hentz, Nathan L. Kobrinsky, Paul J. Galardy, Jacob R Greenmyer

Blood (2023) 142 (Supplement 1): 5350.

https://doi.org/10.1182/blood-2023-182092

Published: 2023

Journal Articles

Correlation of Minimal Residual Disease (MRD) at the End of Induction (EOI) and Event Free Survival (EFS) in T-Cell Lymphoblastic Lymphoma (T-LL), a Report from the Children's Oncology Group (COG) Trial AALL1231

Blood (2022) 140 (Supplement 1): 6387–6389.

https://doi.org/10.1182/blood-2022-159694

Published: 2022

Journal Articles

Cranial Radiation Can be Eliminated in Most Children with T-Cell Acute Lymphoblastic Leukemia (T-ALL) and Bortezomib Potentially Improves Survival in Children with T-Cell Lymphoblastic Lymphoma (T-LL): Results of Children's Oncology Group (COG) Trial AALL1231

Blood (2020) 136 (Supplement 1): 11–12.

https://doi.org/10.1182/blood-2020-134730

Published: 2020

Journal Articles

UCH-L1 bypasses mTOR to promote protein biosynthesis and is required for MYC-driven lymphomagenesis in mice

Sajjad Hussain, Tibor Bedekovics, Qiuying Liu, Wenqian Hu, Haeseung Jeon, Sarah H. Johnson, George Vasmatzis, Danielle G. May, Kyle J. Roux, Paul J. Galardy

Blood (2018) 132 (24): 2564–2574.

https://doi.org/10.1182/blood-2018-05-848515

Published: 2018

Includes: Supplemental data

Journal Articles

Catalytically Active UCH-L1 Is Required for MYC Driven B-Cell Lymphomagenesis

Tibor Bedekovics, PhD, Sajjad Hussain, PhD MSC, Paul J. Galardy, MD

Blood (2017) 130 (Supplement 1): 644.

https://doi.org/10.1182/blood.V130.Suppl_1.644.644

Published: 2017

Journal Articles

UCH-L1 is induced in germinal center B cells and identifies patients with aggressive germinal center diffuse large B-cell lymphoma

Tibor Bedekovics, Sajjad Hussain, Andrew L. Feldman, Paul J. Galardy

Blood (2016) 127 (12): 1564–1574.

https://doi.org/10.1182/blood-2015-07-656678

Published: 2016

Includes: Supplemental data

Journal Articles

UCHL1 Is a Biomarker of Aggressive Multiple Myeloma Required for Disease Progression

Sajjad Hussain, PhD, Tibor Bedekovics, PhD, Marta Chesi, PhD, Leif Bergsagel, MD PhD, Paul J. Galardy, MD

Blood (2015) 126 (23): 2980.

https://doi.org/10.1182/blood.V126.23.2980.2980

Published: 2015

Journal Articles

Ibrutinib Significantly Prolonged Survival in a Human Burkitt Lymphoma (BL) Xenograft NSG Mouse Model: Ibrutinib May be a Potential Adjuvant Agent in the Treatment of BL

Sanghoon Lee, PhD MSc., Changhong Yin, MD MS, Janet Ayello, MS, Erin Morris, RN, Timmy O'Connell, MS, Lauren Harrison, RN, MSN, Carmella van de Ven, MA, Matthew J. Barth, MD, Rodney R. Miles, MD PhD, Paul J. Galardy, MD, Stanton Goldman, MD, Megan S Lim, MD PhD, Michelle L. Hermiston, MD PhD, Linda McAllister-Lucas, MDPhD, Lisa Giulino-Roth, MD, Sherrie L. Perkins, MD PhD, Mitchell S. Cairo, MD

Blood (2015) 126 (23): 5117.

https://doi.org/10.1182/blood.V126.23.5117.5117

Published: 2015

Journal Articles

Ibrutinib Alone and in Combination with Dexamethasone and Carfilzomib Significantly Inhibits Cell Proliferation in Primary Mediastinal B-Cell Lymphoma (PMBL): Ibrutinib May be a Future Targeted Agent in Combination Therapy in Patients with PMBL

Sanghoon Lee, PhD MSc., Changhong Yin, MD MS, Janet Ayello, MS, Erin Morris, RN, Lauren Harrison, RN, MSN, Carmella van de Ven, MA, Matthew J. Barth, MD, Rodney R. Miles, MD PhD, Paul J. Galardy, MD, Stanton Goldman, MD, Megan S Lim, MD PhD, Michelle L. Hermiston, MD PhD, Linda McAllister-Lucas, MDPhD, Lisa Giulino-Roth, MD, Sherrie L. Perkins, MD PhD, Mitchell S. Cairo, MD

Blood (2015) 126 (23): 4852.

https://doi.org/10.1182/blood.V126.23.4852.4852

Published: 2015

Journal Articles

UCH-L1 Cooperates with BCL6 and Identifies Patients with Aggressive Germinal Center Diffuse Large B-Cell Lymphoma

Tibor Bedekovics, PhD, Sajjad Hussain, PhD, Andrew L Feldman, MD, Paul J. Galardy, MD

Blood (2015) 126 (23): 2673.

https://doi.org/10.1182/blood.V126.23.2673.2673

Published: 2015

Journal Articles

The Efficacy of Rasburicase and Rituximab Combined with FAB Chemotherapy in Children and Adolescents with Newly Diagnosed Stage III/IV, BM+ and CNS+ Mature B-NHL: A Children's Oncology Group Report

Stanton Goldman, MD, Paul J. Galardy, MD, Lynette Smith, MS, Sherrie L. Perkins, MD, PhD, Bruce Shiramizu, MD, Thomas Gross, MD, PhD, Warren G. Sanger, PhD, Lauren Harrison, RN, MSN, Mitchell S. Cairo, MD

Blood (2011) 118 (21): 2702.

https://doi.org/10.1182/blood.V118.21.2702.2702

Published: 2011

Journal Articles

UCH-L1 Is a Novel Regulator of mTOR Signaling That May Predict a Poor Response to mTOR Inhibition in Patients with B-Cell Lymphoma,

Sajjad Hussain, PhD, Steven C. Ziesmer, Andrew L. Feldman, MD, Stephen M. Ansell, MD, PhD, Paul J. Galardy, MD

Blood (2011) 118 (21): 3691.

https://doi.org/10.1182/blood.V118.21.3691.3691

Published: 2011

Journal Articles

UCH-L1, a Potent Oncogene That Drives the Development of B-Cell Lymphoma, Promotes Akt Signaling by Regulating Mtor Complex Assembly

Sajjad Hussain, PhD, Paul J. Galardy, MD

Blood (2010) 116 (21): 4182.

https://doi.org/10.1182/blood.V116.21.4182.4182

Published: 2010

Journal Articles

USP44 Is Highly Over-Expresed In T-Cell Acute Lymphoblastic Leukemia and Leads to the Development of Chromosome Missegregation and Aneupoloidy

Paul J. Galardy, MD, Ying Zhang, PhD

Blood (2010) 116 (21): 29.

https://doi.org/10.1182/blood.V116.21.29.29

Published: 2010

Journal Articles

UCH-L1 Provides An Essential Survival Signal in Malignant B-Cells by Enhancing NF-κB Activation.

Sajjad Hussain, PhD, Paul J. Galardy, MD

Blood (2008) 112 (11): 3338.

https://doi.org/10.1182/blood.V112.11.3338.3338

Published: 2008

Journal Articles

The IL-2 Induced De-Ubiquitinating Enzyme, DUB-2, Is a Nuclear-Cytoplasmic Shuttle Which Requires Catalytic Activity for Nuclear Localization.

Paul J. Galardy, MD, Alan D. D’Andrea, M.D., Hidde L. Ploegh, Ph.D.

Blood (2006) 108 (11): 868.

https://doi.org/10.1182/blood.V108.11.868.868

Published: 2006

NARROW

MRD at the end of induction and EFS in T-cell lymphoblastic lymphoma: Children’s Oncology Group trial AALL1231

Neonatal Hemophagocytic Lymphohistiocytosis: Scoping Review and Analysis of 205 Cases

Correlation of Minimal Residual Disease (MRD) at the End of Induction (EOI) and Event Free Survival (EFS) in T-Cell Lymphoblastic Lymphoma (T-LL), a Report from the Children's Oncology Group (COG) Trial AALL1231

Cranial Radiation Can be Eliminated in Most Children with T-Cell Acute Lymphoblastic Leukemia (T-ALL) and Bortezomib Potentially Improves Survival in Children with T-Cell Lymphoblastic Lymphoma (T-LL): Results of Children's Oncology Group (COG) Trial AALL1231

UCH-L1 bypasses mTOR to promote protein biosynthesis and is required for MYC-driven lymphomagenesis in mice

Catalytically Active UCH-L1 Is Required for MYC Driven B-Cell Lymphomagenesis

UCH-L1 is induced in germinal center B cells and identifies patients with aggressive germinal center diffuse large B-cell lymphoma

UCHL1 Is a Biomarker of Aggressive Multiple Myeloma Required for Disease Progression

Ibrutinib Significantly Prolonged Survival in a Human Burkitt Lymphoma (BL) Xenograft NSG Mouse Model: Ibrutinib May be a Potential Adjuvant Agent in the Treatment of BL

Ibrutinib Alone and in Combination with Dexamethasone and Carfilzomib Significantly Inhibits Cell Proliferation in Primary Mediastinal B-Cell Lymphoma (PMBL): Ibrutinib May be a Future Targeted Agent in Combination Therapy in Patients with PMBL

UCH-L1 Cooperates with BCL6 and Identifies Patients with Aggressive Germinal Center Diffuse Large B-Cell Lymphoma

The Efficacy of Rasburicase and Rituximab Combined with FAB Chemotherapy in Children and Adolescents with Newly Diagnosed Stage III/IV, BM+ and CNS+ Mature B-NHL: A Children's Oncology Group Report

UCH-L1 Is a Novel Regulator of mTOR Signaling That May Predict a Poor Response to mTOR Inhibition in Patients with B-Cell Lymphoma,

UCH-L1, a Potent Oncogene That Drives the Development of B-Cell Lymphoma, Promotes Akt Signaling by Regulating Mtor Complex Assembly

USP44 Is Highly Over-Expresed In T-Cell Acute Lymphoblastic Leukemia and Leads to the Development of Chromosome Missegregation and Aneupoloidy

UCH-L1 Provides An Essential Survival Signal in Malignant B-Cells by Enhancing NF-κB Activation.

The IL-2 Induced De-Ubiquitinating Enzyme, DUB-2, Is a Nuclear-Cytoplasmic Shuttle Which Requires Catalytic Activity for Nuclear Localization.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only